Not exact matches
Approximately 175000 cancer cases are diagnosed annually in children younger than
age 15 years worldwide, 1 with an annual increase
of around 0.9 % in incidence rate in the developed world, only partly explained by improved
diagnosis and reporting.1, 2 Childhood cancer is rare and its survival rate has increased significantly over the years owing to advancement in treatment technologies; however, it is still a leading cause
of death among children and adolescents in developed countries, ranking second among children
aged 1 to 14 years in the United States, surpassed only by accidents.1, 3 Childhood cancer is also emerging as a major cause
of death in the last few years in Asia, Central and South America, Northwest Africa, and the Middle East, where death rates from preventable communicable diseases are
declining.2
It is important for physicians and scientists to understand the unique pathology
of HS -
AGING, and to be able to differentiate it from other diseases, as it is only by making an accurate
diagnosis that clinicians can hope to treat people who present with signs
of cognitive
decline.
The potential for early
diagnosis and delaying the onset
of motor or cognitive
decline by perhaps ten years is
of potentially profound importance in an
aging society.»
I've written about the use
of neuropsychological tests for the differential
diagnosis of AD, MCI, normal cognitive
aging, and other neurodegenerative diseases, as well as for the prediction
of cognitive
decline and conversion from MCI to dementia.
We defined adult - onset MDD as a first
diagnosis at 17 years or older because (1) this cutoff was consistent with the definition
of adult - onset MDD used by Harrington et al2 and (2) the incidence
of new cases
of depression in this sample spiked between the
ages of 15 and18 years and
declined thereafter, suggesting that onset
of depression at or before
age 15 years is unique (Figure 1).27